These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31884676)

  • 1. Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Dos Santos G; Nguyen BY; Damaso S; Godderis L; Martínez-Gómez X; Eckermann T; Loos H; Salamanca de la Cueva I; Shende V; Schmidt AC; Yeakey A
    Drug Saf; 2020 Mar; 43(3):265-279. PubMed ID: 31884676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Salamanca de la Cueva I; Cinconze E; Eckermann T; Nwoji U; Godderis L; Lu E; Martínez-Gómez X; Wang H; Yanni E
    Drug Saf; 2021 Dec; 44(12):1375-1390. PubMed ID: 34694589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis.
    Dos Santos G; Shende V; Damaso S; Yeakey A
    Adv Ther; 2019 Dec; 36(12):3340-3355. PubMed ID: 31595482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season.
    Dos Santos G; Wang H; Jindal P; Rybo M; Roul H; Pallem S; Eckermann T; Godderis L; Martínez Gómez X; Godard E; Soler M; Yousefi M; Salamanca de la Cueva I; Nwoji U
    Infect Dis Ther; 2022 Feb; 11(1):463-483. PubMed ID: 34961900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient-reported outcome system for vaccine safety remote monitoring.
    Dos Santos G; Eckermann T; Martínez-Gómez X; Parra J; Nwoji U; Salamanca de la Cueva I
    Influenza Other Respir Viruses; 2023 Mar; 17(3):e13098. PubMed ID: 36991538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season.
    de la Cueva IS; Gerber JE; Hastie A; Brotons C; Panzer F; Pirçon JY; Talsma P; Eckermann T; Nikic V; Gomez XM; Alsdurf H
    Drug Saf; 2024 Jun; ():. PubMed ID: 38949714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older.
    Dos Santos G; Devadiga R; Kim CS; Bang J
    Drug Saf; 2024 Apr; 47(4):365-375. PubMed ID: 38483767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season.
    Dos Santos G; Yeakey A; Shende V; Smith K; Lin F; Zandman-van-Dijk E; Damaso S; Schmidt A
    BMJ Open; 2019 Aug; 9(8):e028043. PubMed ID: 31427321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis.
    de Lusignan S; Dos Santos G; Byford R; Schuind A; Damaso S; Shende V; McGee C; Yonova I; Ferreira F
    Adv Ther; 2018 Aug; 35(8):1199-1214. PubMed ID: 29995300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21.
    Syrkina O; Inamdar A; Wague S; Monfredo C; Nissilä M; Chabanon AL; Serradell L
    BMC Public Health; 2022 Aug; 22(1):1506. PubMed ID: 35941631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season.
    Chabanon AL; Wague S; Moureau A; Nissila M; Serradell L
    BMC Public Health; 2021 Feb; 21(1):358. PubMed ID: 33588815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brand-specific enhanced safety surveillance of GSK's Fluarix Tetra seasonal influenza vaccine in England: 2017/2018 season.
    de Lusignan S; Damaso S; Ferreira F; Byford R; McGee C; Pathirannehelage S; Shende V; Yonova I; Schmidt A; Schuind A; Dos Santos G
    Hum Vaccin Immunother; 2020 Aug; 16(8):1762-1771. PubMed ID: 32118513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card.
    de Lusignan S; Ferreira F; Damaso S; Byford R; Pathirannehelage S; Yeakey A; Yonova I; Schuind A; Dos Santos G
    Hum Vaccin Immunother; 2019; 15(5):1048-1059. PubMed ID: 30648923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study.
    Stuurman AL; Verstraeten T; De Schryver A
    Expert Rev Vaccines; 2017 Feb; 16(2):187-191. PubMed ID: 27882801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England.
    de Lusignan S; Dos Santos G; Correa A; Haguinet F; Yonova I; Lair F; Byford R; Ferreira F; Stuttard K; Chan T
    BMJ Open; 2017 May; 7(5):e015469. PubMed ID: 28515198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the influenza season 2021/22.
    Gandhi-Banga S; Wague S; Shrestha A; Syrkina O; Talanova O; Nissilä M; Stuff K; Monfredo C
    Influenza Other Respir Viruses; 2023 Jan; 17(1):e13071. PubMed ID: 36448240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.